NEW YORK (GenomeWeb) – HTG Molecular Diagnostics has appealed a delisting determination by Nasdaq after the company's shares failed to regain compliance with a listing requirement, the firm said in a document filed with the US Securities and Exchange Commission after the close of the market on Tuesday.

The company had been warned in August 2016 by Nasdaq that it failed to comply with a minimum $10 million stockholder equity requirement to remain listed on the exchange. HTG Molecular was given an extension until Feb. 13 to regain compliance.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.